Profit before tax fell 3.74% to Rs 100.27 crore in Q4 FY24 as compared to Rs 104.17 crore in Q4 FY23.

EBITDA rose marginally to Rs 109.6 crore in Q4 FY24 as compared to Rs 109.5 crore in Q4 FY23. EBITDA margin reduced to 19.6% in the fourth quarter as compared to 22.5% in the corresponding period last year, surge in freight cost, transit time due to red sea crisis, increase in expenses related to Teva acquisition and increased hiring in the new plant in Q4FY24 led to impact on EBITDA.

During the quarter, revenue from US & North America stood at Rs 245 crore (up 26.5% YoY) while UK and Europe stood at Rs 232.8 crore (up 12.9% YoY).

Revenue from Australia and New Zealand business stood at Rs 63.3 crore (down 0.1% YoY) in Q4 FY24.

Rest of World (ROW) business de-grew by 17.1% YoY to Rs 18.9 crore during the period under review.

On a full year basis, the company reported a consolidated profit climbed 18.68% to Rs 314.89 crore on 17.56% increase in revenue from operations 2,177.40 crore in FY24 over FY23.

Meanwhile, the board has declared a dividend of Rs 0.60 per share for the financial year ended 2024, The dividend will be paid within 30 days from the date of the AGM.

Mark Saldanha, managing director, Marksans Pharma, said, “We are delighted to report a strong performance in FY24 in terms of both revenue and profitability. Our operating revenue for the year grew year-on-year by 18% and EBITDA increased by 35%, supported by new product launches, increase in market share, reduction in raw material prices and operating leverage. This year we have not only met but exceeded our revenue target of Rs 2,000 crore.

We remain confident on delivering sustained long-term value for our shareholders, as we position ourselves strongly in terms of infrastructure, product mix and long-term customer relationships.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.